Renaissance Capital logo

bluebird bio Priced, Nasdaq: BLUE

Developing gene therapies for severe genetic and orphan diseases.

Industry: Health Care

First Day Return: +58.3%

Developing gene therapies for severe genetic and orphan diseases.

bluebird bio (BLUE) Performance

Created with Highcharts 10.3.2Chart context menuBLUE vs. IPO Index (IPOUSA)2014201520162017201820192020202120222023202420250%+ 200%+ 400%-200%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index